Effect of rat kidney fraction 3 (rKF3) antigen and specific IgM antibody against rKF3 on the progression of slowly progressive Heymann nephritis

Pathology International

Volumn 56, Issue 9, 2006, Pages 516-529

  Barabas, Arpad Zsigmond ^a   Cole, Chad Douglas ^b   Barabas, Arpad David ^a   Barabas, Aron Nicholas ^a   Lafreniere, Rene ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune; Immune complex glomerulonephritis; Non pathogenic IgM autoantibody; Pathogenic IgG autoantibody; Slowly progressive Heymann nephritis

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; NEPHRITOGENIC ANTIGEN; RAT KIDNEY FRACTION 3 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE COURSE; GLOMERULUS; HEYMANN NEPHRITIS; IMMUNOGLOBULIN PRODUCTION; MALE; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT;

EID: 33747455592     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2006.02000.x     Document Type: Article

References (69)

1. Chen ZJ, Wheeler J, Notkins AL. Antigen-binding B cells and polyreactive antibodies. Eur J Immunol 1995; 25: 579-86.
2. Liu Y, Janeway CA Jr. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci USA 1992; 89: 3845-9.
3. Miller JF, Basten A. Mechanisms of tolerance to self. Curr Opin Immunol 1996; 8: 815-21.
4. Shevach EM. Regulatory T cells in autoimmunity. Annu Rev Immunol 2000; 18: 423-49.
5. Theofilopoulos AN. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol Today 1995; 16: 90-98.
6. Garza KM, Chan SM, Suri R et al. Role of antigen-presenting cells in mediating tolerance and autoimmunity. J Exp Med 2000; 191: 2021-7.
7. Ludewig B, Junt T, Hengartner H, Zinkernagel RM. Dendritic cells in autoimmune diseases. Curr Opin Immunol 2001; 13: 657-62.
8. Weir DM, Pinckard RN, Elson CJ, Suckling DE. Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol 1966; 1: 433-42.
9. Barabas AZ, Cole CD, Barabas AD et al. Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int J Exp Pathol 2004; 85: 201-12.
10. Naito T, Kawamura T, Bannai M et al. Simultaneous activation of natural killer T cells and autoantibody production in mice injected with denatured syngeneic liver tissue. Clin Exp Immunol 2002; 129: 397-404.
11. Schoen RT, Trentham DE. Drug-induced lupus: An adjuvant disease? Am J Med 1981; 71: 5-8.
12. Totoritis MC, Rubin RL. Drug-induced lupus. Genetic, clinical, and laboratory features. Postgrad Med 1985; 78: 149-61.
13. Weir DM. Altered antigens and autoimmunity. Vox Sang 1969; 16: 304-13.
14. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of a new model of slowly progressive Heymann nephritis. Int J Exp Pathol 2003; 84: 245-58.
15. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol 2004; 85: 277-85.
16. Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JLP. Production of the nephritic syndrome in rat by Freund's adjuvant and rat kidney suspension. Proc Soc Exp Biol Med 1959; 100: 660-64.
17. Mendrick DL, Noble B, Brentjens JR, Andres GA. Antibody-mediated injury to proximal tubules in Heymann nephritis. Kidney Int 1980; 18: 328-43.
18. Raychowdhury R, Zheng G, Brown D, McCluskey RT. Induction of Heymann nephritis with a gp330/megalin fusion protein. Am J Pathol 1996; 148: 1613-23.
19. Salant DJ, Cybulsky AV. Experimental glomerulonephritis. Methods Enzymol 1988; 162: 421-61.
20. Makker SP. Heymann nephritis of rats: Beneficial effect of methysergide. J Lab Clin Med 1977; 90: 796-802.
21. Barabas AZ, James K, Lannigan R. Preliminary observations on the effect of heterologous anti-lymphocytic globulin on autologous immune complex nephritis in rats. Clin Exp Immunol 1969; 5: 419-27.
22. Barabas AZ, Nagi AH, Lannigan R, Womersley RA. The effect of cortisone treatment on autologous immune complex glomerulonephritis in rats. Br J Exp Pathol 1970; 51: 541-6.
23. Nangaku M, Pippin J, Richardson CA et al. Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy. Kidney Int 1996; 50: 2054-62.
24. Hasegawa Y, Kaneoka H, Tanaka T et al. Suppression of experimental membranous glomerulonephritis in rats by an anti-MHC class II antibody. Nephron 2001; 88: 233-40.
25. Cattran DC. Effect of ciclosporin on active Heymann nephritis. Nephron 1988; 48: 142-8.
26. Fleuren GJ, Hoedemaeker PJ. Triple-drug treatment of autologous immune complex glomerulonephritis. Clin Exp Immunol 1980; 41: 218-24.
27. Kupor LR, Lowance DC, McPhaul JJ Jr. Single and multiple drug therapy in autologous immune complex nephritis in rats. J Lab Clin Med 1976; 87: 27-36.
28. Lim VS, Spargo B. Immunosuppressive treatment of autologous immune complex nephritis in rats. J Lab Clin Med 1973; 81: 661-70.
29. Matsukawa W, Hara S, Yoshida F et al. Effects of a new immunosuppressive agent, FK506, in rats with active Heymann nephritis. J Lab Clin Med 1992; 119: 116-23.
30. Peakman M, Dayan CM. Antigen-specific immunotherapy for autoimmune disease: Fighting fire with fire? Immunology 2001; 104: 361-6.
31. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol 2004; 85: 321-34.
32. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Down-regulation of pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int 2006; 56: 181-90.
33. Singh AK, Makker SP. Circulatory antigens of Heymann nephritis. I. Identification and partial characterization. Immunology 1986; 57: 467-72.
34. Higgins PJ, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol 1988; 140: 440-45.
35. Thompson HSG, Staines NA. Gastric administration of type II collagen delays the onset and severity of collegen induced arthritis in rats. Clin Exp Immunol 1985; 64: 581-6.
36. Bitar DM, Whitacre CC. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell Immunol 1988; 112: 364-70.
37. Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 1986; 83: 7443-6.
38. Trentham DE, Dynesius-Trentham RA, Orav EJ et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993; 261: 1727-30.
39. Weiner HL, Mackin GA, Matsui M et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259: 1321-4.
40. Weiner HL. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997; 18: 335-43.
41. Kamata K, Baird LG, Erikson ME, Collins AB, McCluskey RT. Characterization of antigens and antibody specificities involved in Heymann nephritis. J Immunol 1985; 135: 2400-8.
42. Makker SP. Analysis of glomeruli-eluted Gp330 autoantibodies and of Gp330 antigen of Heymann nephritis. J Immunol 1993; 151: 6500-8.
43. Noble B, Van Liew JB, Brentjens JR, Andres GA. Effect of reimmunization with Fx1A late in the course of Heymann nephritis. Lab Invest 1982; 47: 427-36.
44. Barabas AZ, Elson CJ, Weir DM. The serology of autologous immune complex nephritis in the rat. Clin Exp Immunol 1969; 4: 345-51.
45. Andres G, Brentjens JR, Caldwell PR, Camussi G, Matsuo S. Formation of immune deposits and disease. Lab Invest 1986; 55: 510-20.
46. Barabas AZ, Lannigan R. Auto-immune nephritis in rats. J Pathol 1969; 97: 537-43.
47. Watson JI, Dixon FJ. Experimental glomerulonephritis. IX: Factors influencing the development of kidney in adjuvant nephritis in rats. Proc Soc Exp Biol Med 1966; 121: 216-23.
48. Hancock WW, Polanski M, Zhang J, Blogg N, Weiner HL. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Am J Pathol 1995; 147: 1193-9.
49. Javed NH, Gienapp IE, Cox KL, Whitacre CC. Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis. J Immunol 1995; 155: 1599-605.
50. Thompson HS, Harper N, Bevan DJ, Staines NA. Suppression of collagen-induced arthritis by oral administration of type II collagen: Changes in immune and arthritic responses mediated by active peripheral suppression. Autoimmunity 1993; 16: 189-99.
51. Wang ZY, Huang J, Olsson T, He B, Link H. B cell responses to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis. J Neurol Sci 1995; 128: 167-74.
52. Whitacre CC, Gienapp IE, Orosz CG, Bitar DM. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J Immunol 1991; 147: 2155-63.
53. Choy EH, Scott DL, Kingsley GH et al. Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum 2001; 44: 1993-7.
54. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000.
55. Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91: 169-72.
56. Lin CY, Hsu HC, Chiang H. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 1989; 53: 303-10.
57. ter Borg EJ, Kallenberg CG. Treatment of severe thrombocytopenia in systemic lupus erythematosus with intravenous gammaglobulin. Ann Rheum Dis 1992; 51: 1149-51.
58. Bruley-Rosset M, Mouthon L, Chanseaud Y, Dhainaut F, Lirochon J, Bourel D. Polyreactive autoantibodies purified from human intravenous immunoglobulins prevent the development of experimental autoimmune diseases. Lab Invest 2003; 83: 1013-23.
59. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228-31.
60. Jordan SC. Intravenous gamma-globulin therapy in systemic lupus erythematosus and immune complex disease. Clin Immunol Immunopathol 1989; 53: S164-9.
61. Mobini N, Sarela A, Ahmed AR. Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders. Ann Allergy Asthma Immunol 1995; 74: 119-28.
62. Nydegger UE, Sultan Y, Kazatchkine MD. The concept of anti-idiotypic regulation of selected autoimmune diseases by intravenous immunoglobulin. Clin Immunol Immunopathol 1989; 53: S72-S82.
63. Palla R, Cirami C, Panichi V, Bianchi AM, Parrini M, Grazi G. Intravenous immunoglobulin therapy of membranous nephropathy: Efficacy and safety. Clin Nephrol 1991; 35: 98-104.
64. Heymann W, Grupe WE. Immune tolerance to experimental autoimmune nephrosis in rats. Proc Soc Exp Biol Med 1970; 135: 184-7.
65. Rich MW. Drug-induced lupus. The list of culprits grows. Postgrad Med 1996; 100: 299-308.
66. Yung RL, Johnson KJ, Richardson BC. New concepts in the pathogenesis of drug-induced lupus. Lab Invest 1995; 73: 746-59.
67. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999; 341: 2068-74.
68. Gran B, Hemmer B, Vergelli M, McFarland HF, Martin R. Molecular mimicry and multiple sclerosis: Degenerate T-cell recognition and the induction of autoimmunity. Ann Neurol 1999; 45: 559-67.
69. Hughes LE, Bonell S, Natt RS et al. Antibody responses to Acinetobacter spp. and Pseudomonas aeruginosa in multiple sclerosis: Prospects for diagnosis using the myelin-acinetobacter-neurofilament antibody index. Clin Diagn Lab Immunol 2001; 8: 1181-8.